- Home
- PML vs PCRX Comparison
PML vs PCRX Comparison
Compare PML & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PML
- PCRX
- Stock Information
- Founded
- PML 2002
- PCRX 2006
- Country
- PML United States
- PCRX United States
- Employees
- PML N/A
- PCRX N/A
- Industry
- PML Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PML Finance
- PCRX Health Care
- Exchange
- PML Nasdaq
- PCRX Nasdaq
- Market Cap
- PML 593.8M
- PCRX 604.7M
- IPO Year
- PML N/A
- PCRX 2011
- Fundamental
- Price
- PML $8.58
- PCRX $17.38
- Analyst Decision
- PML
- PCRX Buy
- Analyst Count
- PML 0
- PCRX 10
- Target Price
- PML N/A
- PCRX $26.60
- AVG Volume (30 Days)
- PML 188.0K
- PCRX 547.0K
- Earning Date
- PML 01-01-0001
- PCRX 11-06-2024
- Dividend Yield
- PML 5.65%
- PCRX N/A
- EPS Growth
- PML N/A
- PCRX N/A
- EPS
- PML N/A
- PCRX N/A
- Revenue
- PML N/A
- PCRX $694,957,000.00
- Revenue This Year
- PML N/A
- PCRX $4.59
- Revenue Next Year
- PML N/A
- PCRX N/A
- P/E Ratio
- PML N/A
- PCRX N/A
- Revenue Growth
- PML N/A
- PCRX 4.40
- 52 Week Low
- PML $6.92
- PCRX $11.16
- 52 Week High
- PML $9.46
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- PML 34.78
- PCRX 58.45
- Support Level
- PML $8.71
- PCRX $16.00
- Resistance Level
- PML $8.82
- PCRX $18.34
- Average True Range (ATR)
- PML 0.14
- PCRX 0.84
- MACD
- PML -0.03
- PCRX -0.05
- Stochastic Oscillator
- PML 1.47
- PCRX 58.97
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.